# Seres Therapeutics to Host Third Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2016

November 4, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2016 at 8:00 a.m. ET to discuss third quarter 2016 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9944547. To join the live webcast, please visit the "Investors and Media" section of the Seres website at  www.serestherapeutics.com.

A webcast replay with corresponding slides will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

**About Seres Therapeutics**

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres' program SER-109 continues to be evaluated in a Phase 2 study in multiply recurrent *C.* difficile infection. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161104005093/en/

Source: Seres Therapeutics, Inc.

**IR and PR Contact:**
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com